Business context and reporting period
This is Dynamics Special Purpose Corp.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not an operating-company quarterly report for Senti Biosciences Holdings, Inc. Dynamics was a shell SPAC seeking to merge with Senti; the proposed transaction had not closed by quarter-end. The comparison period is March 1–31, 2021, the SPAC’s first month after incorporation, so it is not a like-for-like prior-year quarter.
Financial results and liquidity
- Revenue: None. The SPAC had not commenced operations and expected no operating revenue before a business combination.
- Net loss: $1.31 million for Q1 2022, versus $1,178 in the March 2021 inception period. Q1 loss included $1.28 million of professional fees and other expenses and $50,269 of franchise tax expense, partly offset by $23,162 of trust-account interest and dividend income.
- Cash flow: $492,630 used in operating activities. Cash outside the trust account declined to $396,693 from $889,323 at December 31, 2021.
- Assets and liabilities: Total assets were $230.92 million, including $230.03 million held in the trust account. Total liabilities were $11.10 million: $4.05 million current liabilities and a $7.05 million deferred underwriting fee payable upon a completed business combination.
- Working capital: Management reported a $3.22 million working capital deficit. No debt balance or operating margins were reported; the filing describes no operating business or revenue.
Material changes and proposed transaction
Compared with December 31, 2021, outside-trust cash fell by $492,630, total liabilities increased by about $769,000, and accumulated deficit increased by $1.31 million. Trust investments increased by about $23,000.
The December 2021 merger agreement contemplated acquiring Senti at an implied equity value of $240 million, with Senti surviving as a wholly owned subsidiary. The transaction also contemplated a $66.8 million private investment at $10 per share and required at least $150 million of available closing cash after stockholder redemptions. Both the merger and financing remained subject to closing conditions, including approvals and Nasdaq listing approval. The agreement included potential Senti stockholder earnout shares tied to post-closing share-price thresholds.
Outlook, risks, and unusual items
- Going concern: Management said the low outside-trust cash, working capital deficit, and expected transaction costs raised substantial doubt about the SPAC’s ability to continue as a going concern for one year after issuance. Its plan depended on completing the Senti merger; success was not assured. The statements include no adjustments for the uncertainty.
- Timing: The SPAC had until May 28, 2023 to complete a business combination or redeem public shares and liquidate, subject to the filing’s terms.
- Financing and redemptions: Redemptions could reduce closing cash below the agreement’s $150 million condition. The filing disclosed non-redemption arrangements with certain investors, with related share transfers and sponsor share forfeitures contingent on closing.
- Contingent costs: In addition to the $7.05 million deferred underwriting fee, the SPAC would owe a $1 million financial-advisory fee upon closing and placement-agent fees equal to 4% of subscription proceeds.
- Other risks: Management cited potential effects from COVID-19, Russia’s invasion of Ukraine and related sanctions, market volatility, and financing availability. A purported shareholder demand letter alleged material omissions in the merger registration statement; the company said it believed the claims were without merit. No pending litigation was reported.
- Controls: The filing described a prior material weakness involving accounting for complex financial instruments and restatements of earlier financial statements. Management said remediation was planned but could not assure it would be effective; no materially affecting control changes occurred during the quarter.
Key facts investors should verify
- Whether and on what terms the merger and PIPE financing ultimately closed, including actual redemptions and closing cash.
- How the SPAC’s going-concern uncertainty and the $150 million minimum-cash condition were resolved.
- The final effects of amendments to non-redemption agreements and related sponsor share forfeitures and investor share issuances.
- Whether the historical accounting material weakness was remediated and whether subsequent filings disclose further restatements or control deficiencies.
- The status and resolution of the shareholder demand and any related disclosures or litigation.